ImmunoPrecise Antibodies Ltd. (IPA)
After hours:
| Previous Close | 1.2200 |
| Open | 1.2300 |
| Bid | 1.3000 x 100 |
| Ask | 1.3600 x 100 |
| Day's Range | 1.2092 - 1.3300 |
| 52 Week Range | 0.9400 - 4.2200 |
| Volume | |
| Avg. Volume | 597,936 |
| Market Cap | 34.736M |
| Beta (5Y Monthly) | 0.33 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4700 |
| Earnings Date | Jul 05, 2024 - Jul 09, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.01 |
ACCESSWIREEpitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical Materials Needed, Matches Classical Wet Lab Binning Results
VICTORIA, BC / ACCESSWIRE / April 22, 2024 / ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, has recently announced an expansion of its already successful LENSai TM Platform. LENSai, which is ...
- ACCESSWIRE
ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments
VICTORIA, BC / ACCESSWIRE/ April 12, 2024 / InterSystems, a creative data technology provider dedicated to helping customers solve their most critical scalability, interoperability and speed challenges partnered with ImmunoPrecise Antibodies (NASDAQ:IPA) ...
Business WireInterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications
VICTORIA, British Columbia, March 28, 2024--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA), InterSystems, a creative data technology provider dedicated to helping customers solve their most critical scalability, interoperability, and speed challenges, together with ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, are thrilled to announce a landmark collaboration. This collaboration int
